Barry H. Greenberg, MD, of the University of California, San Diego, talks with DocWire News about his presentation of a update for COMMANDER-HF at the American Heart Association 2018 Scientific Sessions in Chicago.
The COMMANDER-HF study included 5,022 patients with chronic HF, left ventricular ejection fraction ≤40%, CAD, increased plasma natriuretic peptide concentrations and without atrial fibrillation were randomized to either rivaroxaban 2.5 mg twice daily or placebo plus standard care following worsening heart failure.
According to the study results, 718 thrombotic events (including fatal and non-fatal MI, fatal and non-fatal non-hemorrhagic stroke, sudden or unwitnessed death, symptomatic pulmonary embolus and deep venous thrombosis) occurred during a median follow-up period of 21.1 months. Patients receiving rivaroxaban experienced a reduction in time to first thrombotic event from 15.5% to 13.1% (HR=0.83; CI 0.72 to 0.96; P=0.013) due predominantly to reductions in non-fatal MI (HR=0.70; CI 0.51 to 0.96; P=0.026) and non-fatal non-hemorrhagic stroke (HR=0.59; CI 0.39 to 0.91; P=0.017).
Read the full manuscript here.
Read more DocWire News Coverage of AHA 2018 here.